Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Insiders Buying Solid Biosciences And 2 Other Stocks

Published 16/01/2024, 11:17
© Reuters.  Insiders Buying Solid Biosciences And 2 Other Stocks

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

Although U.S. stocks closed mixed on Friday, there were a few notable insider trades.

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

Solid Biosciences

  • The Trade: Solid Biosciences Inc. (NASDAQ: SLDB) Director Joseph Edelman acquired a total of 3,410,713 shares an average price of $5.53. To acquire these shares, it cost around $18.86 million. The company’s 10% owner RA Capital Nexus Fund, L.P also bought 904,160 shares at an average price of $5.53.
  • What’s Happening: Solid Biosciences entered into a securities purchase agreement with a select group of institutional accredited investors for an approximately $108.9 million private placement.
  • What Solid Biosciences Does: Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs.
Champions Oncology
  • The Trade: Champions Oncology, Inc. (NASDAQ: CSBR) Director Daniel Mendelson acquired a total of 2,000 shares at an average price of $6.27. To acquire these shares, it cost around $12,540.
  • What’s Happening: Champions Oncology, last month, posted a loss for the second quarter.
  • What Champions Oncology Does: Champions Oncology Inc is a us-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

AMREP

  • The Trade: AMREP Corporation (NYSE: AXR) 10% owner Rainey Lancaster bought a total of 6,800 shares at an average price of $21.93. To acquire these shares, it cost around $149,120.
  • What’s Happening: Amrep, last month, reported a decline in quarterly sales.
  • What AMREP Does: Amrep Corp through its subsidiaries is engaged in the Real estate business.

Check This Out: Top 4 Tech And Telecom Stocks That May Crash In January

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.